Who is sponsoring NCT05546060?

NCT05546060 is sponsored by Beijing Friendship Hospital.

What drugs are being tested in NCT05546060?

Interventions in NCT05546060: Venetoclax, Dexamethasone, Etoposide.

What condition does NCT05546060 study?

NCT05546060 studies Hemophagocytic Lymphohistiocytosis.

Is NCT05546060 still recruiting?

NCT05546060 is currently status unknown. Last updated 19 September 2022.

Last reviewed 2022-09-19 · How we verify

NCT05546060

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of Venetoclax Combined With Dexamethasone and Etoposide in HLH

Status unknown Phase 1 Last updated 19 September 2022

What this trial tests

Phase 1 trial testing Venetoclax in Hemophagocytic Lymphohistiocytosis in 20 participants. Status unknown.

Timeline

1 July 2022

Primary endpoint
1 July 2025

1 October 2025

Quick facts

Lead sponsor	Beijing Friendship Hospital
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	1 July 2022
Primary completion	1 July 2025
Estimated completion	1 October 2025
Sites	1 location across China

Drugs / interventions tested

Venetoclax (venetoclax) — full drug profile →
Dexamethasone (dexamethasone) — full drug profile →
Etoposide (etoposide) — full drug profile →

Conditions studied

Hemophagocytic Lymphohistiocytosis — all drugs for Hemophagocytic Lymphohistiocytosis →

Sponsor

Beijing Friendship Hospital

Who can join

18 and older, any sex, with Hemophagocytic Lymphohistiocytosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aimed to investigate the efficacy and safety of venetoclax combined with dexamethasone and etoposide as a salvage therapy for hemophagocytic lymphohistiocytosis.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Diagnosis and Management of Adult Malignancy-Associated Hemophagocytic Lymphohistiocytosis.
Lee JC, Logan AC. · · 2023 · cited 27× · PMID 36980725 · DOI 10.3390/cancers15061839
Fever: Harmless Heat or a Deadly Inferno? Unmasking Hemophagocytic Lymphohistiocytosis and Beyond: A Rare Case of Mast Cell Sarcoma and Overview of HLH.
Yagnik KJ, Espiritu A, Rathod M, Unas J, et al · · 2025 · PMID 41211250 · DOI 10.14740/jh2087

Verify or expand the search:

Other trials of Venetoclax

Trials testing the same drug.

NCT07425808 — FLT3-ITD Targeted Therapy in Fit AML Patients · Phase 2, PHASE3 · not yet recruiting
NCT07437950 — Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A Myel · Phase 2 · not yet recruiting
NCT07175415 — HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological · Phase 1, PHASE2 · not yet recruiting
NCT07513129 — A Phase 1 Study Of Venetoclax, Dexamethasone, Bortezomib, And Daratumumab (VDBD) For Adolescent And Young Adult Patients · Phase 1 · not yet recruiting
NCT07511062 — Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML · Phase 1 · not yet recruiting

Other Beijing Friendship Hospital trials

Trials by the same sponsor.

NCT07453862 — Novel Calcium Channel Modulators in RLS and Variants: Efficacy & Safety · Phase 1 · recruiting
NCT07397442 — Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer · Phase 2 · not yet recruiting
NCT07393048 — Application and Exploration of Personalized ctDNA-MRD Detection Technology in Predicting the Efficacy of Neoadjuvant The · recruiting
NCT07441850 — Digital Rehabilitation for Gastric Cancer Surgery After Neoadjuvant Therapy · NA · recruiting
NCT07369739 — Golidocitinib Combined With Selinexor for CAEBVD · Phase 2, PHASE3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05546060 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Beijing Friendship Hospital
Last refreshed: 19 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05546060.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing